JP2024522620A - アトピー性皮膚炎及び関連する障害の治療方法 - Google Patents

アトピー性皮膚炎及び関連する障害の治療方法 Download PDF

Info

Publication number
JP2024522620A
JP2024522620A JP2023575802A JP2023575802A JP2024522620A JP 2024522620 A JP2024522620 A JP 2024522620A JP 2023575802 A JP2023575802 A JP 2023575802A JP 2023575802 A JP2023575802 A JP 2023575802A JP 2024522620 A JP2024522620 A JP 2024522620A
Authority
JP
Japan
Prior art keywords
binding protein
subject
use according
dose
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522620A5 (cg-RX-API-DMAC7.html
Inventor
マーク,トーマス
ソルドブロー,リーセ
ビェアアゴー ウーラン,クリスチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2024522620A publication Critical patent/JP2024522620A/ja
Publication of JP2024522620A5 publication Critical patent/JP2024522620A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2023575802A 2021-06-11 2022-06-10 アトピー性皮膚炎及び関連する障害の治療方法 Pending JP2024522620A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108379.5A GB202108379D0 (en) 2021-06-11 2021-06-11 Methods for treating a topic dermatitis and related disorders
GB2108379.5 2021-06-11
PCT/EP2022/065851 WO2022258814A1 (en) 2021-06-11 2022-06-10 Methods for treating atopic dermatitis and related disorders

Publications (2)

Publication Number Publication Date
JP2024522620A true JP2024522620A (ja) 2024-06-21
JP2024522620A5 JP2024522620A5 (cg-RX-API-DMAC7.html) 2025-06-17

Family

ID=76954592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575802A Pending JP2024522620A (ja) 2021-06-11 2022-06-10 アトピー性皮膚炎及び関連する障害の治療方法

Country Status (9)

Country Link
US (1) US20250059269A1 (cg-RX-API-DMAC7.html)
EP (1) EP4351641A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024522620A (cg-RX-API-DMAC7.html)
AU (1) AU2022289697A1 (cg-RX-API-DMAC7.html)
CA (1) CA3221119A1 (cg-RX-API-DMAC7.html)
GB (1) GB202108379D0 (cg-RX-API-DMAC7.html)
IL (1) IL309053A (cg-RX-API-DMAC7.html)
TW (1) TW202317184A (cg-RX-API-DMAC7.html)
WO (1) WO2022258814A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260234236A1 (en) * 2023-02-13 2026-08-13 Intervet Inc. Canine antibodies to canine il-13

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017139290A1 (en) * 2016-02-10 2017-08-17 Medimmune, Llc Tralokinumab delivery device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
KR101363777B1 (ko) 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―13 항체 조성물
JP2020509025A (ja) 2017-03-01 2020-03-26 メドイミューン・リミテッドMedImmune Limited モノクローナル抗体製剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017139290A1 (en) * 2016-02-10 2017-08-17 Medimmune, Llc Tralokinumab delivery device

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRANCISCA GONCALVES ET AL.: "Selective IL-13 inhibitors for the treatment of atopic dermatitis", DRUGS IN CONTEXT, vol. 10, JPN6026027190, March 2021 (2021-03-01), pages 2021 - 1, ISSN: 0005897417 *

Also Published As

Publication number Publication date
EP4351641A1 (en) 2024-04-17
GB202108379D0 (en) 2021-07-28
AU2022289697A1 (en) 2023-12-21
TW202317184A (zh) 2023-05-01
US20250059269A1 (en) 2025-02-20
WO2022258814A1 (en) 2022-12-15
CA3221119A1 (en) 2022-12-15
IL309053A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
US11167004B2 (en) Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
KR102927870B1 (ko) Il-4r 길항제의 투여에 의한 피부 감염의 치료 방법
JP7609901B2 (ja) Il-4rアンタゴニストを投与することにより喘息を処置又は予防するための方法
RU2759630C2 (ru) Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
WO2021195530A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
US20230167171A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
US12187788B2 (en) Methods for treating atopic dermatitis and related disorders
US20250059269A1 (en) Methods for treating atopic dermatitis and related disorders
EP4126943B1 (en) Methods for treating atopic dermatitis and related disorders
US20240400669A1 (en) Methods for treating atopic dermatitis and related disorders
RU2801204C2 (ru) Способ лечения атопического дерматита посредством введения ингибитора ил-4r

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260630

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260702